iOnctura

iOnctura is a private, clinical-stage biotech developing a pipeline of novel, oral small molecules targeting the tumor microenvironment to overcome stroma and immune-mediated resistance in challenging cancers. Its lead programs include roginolisib (IOA-244), a first-in-class allosteric PI3Kδ modulator, and cambritaxestat (IOA-289), the only autotaxin inhibitor in clinical development for oncology. With a seasoned leadership team, over €100M in private financing, and two programs in mid-stage clinical development, the company is positioned to address significant unmet needs in oncology with potentially differentiated, precision therapies.

Focus on developing novel oral small molecules that target key nodes (e.g., PI3Kδ, autotaxin, TGF-β) within the tumor-stroma-immune interface to overcome therapeutic resistance.

iOnctura faces competition in the PI3Kδ space from other inhibitors (e.g., idelalisib, duvelisib) but aims to differentiate via allosteric modulation for improved safety. In autotaxin inhibition, it appears to be a first-in-class leader for oncology. The TGF-β pathway is competitively targeted by several biopharma companies, making IOA-359's differentiation critical.